Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened immune system or existing liver damage and also in pregnant women, the ...

More information: Shang-Chin Huang et al, All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease, Journal of Hepatology (2024).

AI-assisted adeno-associated virus (AAV) capsid engineering has transformative potential in terms of accelerating and optimizing the development of gene therapies. That’s the view of Fangzhi Tan ...

To survive, bacteria must adapt to ever-changing environments and, as a result, have developed diverse strategies to respond to this challenge. In particular, species from the Mycobacterium genus can ...

– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile ...